Innoviva, Inc. insider trading
Every open-market purchase and sale by Innoviva, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Innoviva, Inc.’s insiders pay?
From February 26, 2010 to March 6, 2025, 19 insiders reported 31 open-market purchases and 34 sales not made under a pre-set plan in Innoviva, Inc. Twelve months after each purchase was reported, the shares were −10.8% against the S&P 500 on average (median −19.9%), over 31 purchases with a full year of prices; 26% beat the index. After sales, the shares moved −8.3% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 1, 2010 into $23,896 by November 2, 2026, +5.4% a year. It held shares 59% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $41,551 (+8.9% a year), and held throughout $90,818 (+14.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Gsk PLC | 10% owner | 20 | −15.2% (20) | 30% | 1 | +24.1% (1) | May 24, 2021 |
| Aguiar Michael W | President & Chief Exec Officer | 0 | — | — | 5 | +5.9% (5) | December 5, 2017 |
| Brinkley David L | Head of Business Dev. | 0 | — | — | 5 | −1.9% (5) | June 1, 2011 |
| Denner Alexander J | 10% owner | 3 | −10.5% (3) | 0% | 1 | +8.1% (1) | March 6, 2025 |
| Witek Theodore J. JR. | Sr. VP & Chief Scientific Off. | 0 | — | — | 4 | −6.7% (4) | August 22, 2018 |
| Zhen Marianne | Chief Accounting Officer | 0 | — | — | 4 | −15.6% (4) | November 17, 2023 |
| Bickerstaff George | Director | 3 | −12.6% (3) | 33% | 0 | — | May 25, 2021 |
| Drazan Jeffrey M | Director | 0 | — | — | 3 | −5.4% (3) | May 2, 2012 |
| Shafer Bradford J | Sr VP, Gen. Counsel, Secretary | 0 | — | — | 3 | −35.4% (3) | August 13, 2014 |
| Young William D | Director | 0 | — | — | 3 | −21.2% (3) | March 9, 2011 |
| Sarissa Capital Management LP | 10% owner | 2 | −7.0% (2) | 0% | 0 | — | June 20, 2023 |
| Abercrombie George B | Sr. VP & Chief Comm. Officer | 0 | — | — | 1 | −2.5% (1) | May 22, 2018 |
| Blum Leonard M | Sr VP, Chief Comm. Officer | 1 | +76.9% (1) | 100% | 0 | — | February 26, 2010 |
| Desparbes Eric | SVP and CFO | 0 | — | — | 1 | −2.5% (1) | May 22, 2018 |
| Hulme Geoffrey | Interim PEO | 1 | −20.9% (1) | 0% | 0 | — | February 20, 2019 |
| Lee Junning | Sr. VP, Technical Operations | 0 | — | — | 1 | −41.3% (1) | August 15, 2014 |
| Mammen Mathai | SVP, Research & Early Clin Dev | 0 | — | — | 1 | +21.0% (1) | September 2, 2010 |
| Raifeld Pavel | Chief Executive Officer | 1 | −3.4% (1) | 0% | 0 | — | March 14, 2023 |
| Waltrip William H | Director | 0 | — | — | 1 | −32.7% (1) | May 29, 2015 |
When several insiders traded Innoviva, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Innoviva, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −21.4% against the index. After 1 selling crowd, −17.2%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 31, 2023 | 3 buying | −12.4% | −8.1% | −11.0% |
| February 28, 2019 | 2 buying | −10.9% | −34.8% | −22.5% |
| December 31, 2010 | 3 selling | −5.4% | −17.2% | −13.7% |